Bell's Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine

被引:25
|
作者
Iftikhar, Haris [1 ]
Noor, Syeda Mishkaat U. [1 ]
Masood, Maarij [1 ]
Bashir, Khalid [1 ]
机构
[1] Hamad Med Corp, Emergency Med, Doha, Qatar
关键词
covid-19; bell's palsy; interferons; stroke; facial nerve; vaccine;
D O I
10.7759/cureus.15935
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Coronavirus disease 2019 (COVID-19) has become the fastest-spreading pandemic of the 21st century. Various vaccines have been made available via emergency use authorization. Currently, two mRNA vaccines are being offered internationally, BNT162b2 and mRNA-1273. In randomized trials of these vaccines, the incidence of Bell's palsy in the vaccinated group does not statistically exceed the placebo group. The FDA recommends increased surveillance for Bell's palsy as a potential side effect with the administration of the vaccines among larger populations globally. There have been a few case reports of Bell's palsy associated with mRNA vaccines. Type I interferons have been proposed as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy. Here, we report the case of a 36-year-old previously healthy patient who developed symptoms of Bell's palsy along with left-arm numbness, tingling, and subjective weakness masquerading as a subacute stroke after receiving the second dose of the mRNA-1273 vaccine. CT and MRI of the brain were unremarkable. He was discharged home with a diagnosis of Bell's palsy and improved on follow-up. mRNA COVID-19 vaccines may be considered a risk factor for Bell's palsy.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
    Jimenez, Moraima
    Roldan, Elisa
    Fernandez-Naval, Candela
    Villacampa, Guillermo
    Martinez-Gallo, Monica
    Medina-Gil, Daniel
    Peralta-Garzon, Soraya
    Pujadas, Gemma
    Hernandez, Cristina
    Pages, Carlota
    Gironella, Mercedes
    Fox, Laura
    Orti, Guillermo
    Barba, Pere
    Pumarola, Tomas
    Cabirta, Alba
    Catala, Eva
    Valentin, Mercedes
    Marin-Niebla, Ana
    Orfao, Alberto
    Gonzalez, Marcos
    Campins, Magda
    Ruiz-Camps, Isabel
    Valcarcel, David
    Bosch, Francesc
    Hernandez, Manuel
    Crespo, Marta
    Esperalba, Juliana
    Abrisqueta, Pau
    BLOOD ADVANCES, 2022, 6 (03) : 774 - 784
  • [42] SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
    Qi, Xian
    Qiu, Haibo
    Bao, Changjun
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (11):
  • [43] Membranous nephropathy following SARS-CoV-2 mRNA-1273 vaccination
    Vongchaiudomchoke, Thanawat
    Cheunsuchon, Boonyarit
    Noppakun, Kajohnsak
    MEDICINA CLINICA, 2023, 161 (11): : 504 - 505
  • [44] Impact of demographics on the inmunogenicity after the third dose of the mRNA-1273 vaccine against the SARS-CoV-2 in cancer patients
    Jimenez Ortega, A.
    Benitez Fuentes, J.
    de Luna Aguilar, A.
    Flores Navarro, P.
    Bartolome Arcilla, J.
    Baos Munoz, E.
    Delgado-Iribarren Garcia-Campero, A.
    Gil Useros, S.
    Perez Segura, P.
    Sanchez-Ramon, S.
    Mohamed Mohamed, K.
    Guevara-Hoyer, K.
    Garcia Bravo, L.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S63 - S63
  • [45] Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients
    Herrera, Sabina
    Colmenero, Jordi
    Pascal, Mariona
    Escobedo, Miguel
    Castel, Maria A.
    Sole-Gonzalez, Eduard
    Palou, Eduard
    Egri, Natalia
    Ruiz, Pablo
    Mosquera, Mar
    Moreno, Asuncion
    Juan, Manel
    Vilella, Anna
    Soriano, Alex
    Farrero, Marta
    Bodro, Marta
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 (12) : 3971 - 3979
  • [46] Delayed Extensive Local Reactions: A Case Series to the mRNA-1273 Vaccine Against SARS-CoV-2
    Ferreira Da Silva, R.
    Ribeiro-Vaz, I.
    Silva, A. M.
    Guedes, P.
    Morato, M.
    Junqueira Polonia, J.
    DRUG SAFETY, 2021, 44 (12) : 1410 - 1410
  • [47] Assessment of Delayed Large Local Reactions After the First Dose of the SARS-CoV-2 mRNA-1273 Vaccine in Japan
    Higashino, Toshihide
    Yamazaki, Yuki
    Senda, Satoko
    Satou, Yushi
    Yonekura, Yuiko
    Imai, Kazuo
    Arakawa, Junko
    Kawano, Shuichi
    Horinosono, Hiroshi
    Miura, Yoshinori
    JAMA DERMATOLOGY, 2022, 158 (08) : 923 - 927
  • [48] Pleuropericardial Effusion and Systemic Inflammatory Syndrome Secondary to the Administration of the mRNA-1273 Vaccine for SARS-CoV-2
    Boira, Ignacio
    Torba, Anastasiya
    Castello, Carmen
    Esteban, Violeta
    Vanes, Sandra
    Chiner, Eusebi
    ARCHIVOS DE BRONCONEUMOLOGIA, 2022, 58 (04): : 372 - 373
  • [49] Delayed Extensive Local Reaction to the mRNA-1273 Vaccine against SARS-CoV-2: A Case Report
    Ferreira-da-Silva, Renato
    Ribeiro-Vaz, Ines
    Silva, Ana Marta
    Nunes, Fernando
    Morato, Manuela
    Polonia, Jorge Junqueira
    Guedes, Paulo
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2022, 13 (04) : 401 - 403
  • [50] Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination
    Maki, Hisataka
    Aikawa, Tadao
    Ibe, Tatsuro
    Oyama-Manabe, Noriko
    Fujita, Hideo
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2022, 23 (02) : E87 - E87